Citations

Showing 10 of 108152 citations.

Addressing Barriers to Reducing Prescribing and Implementing Deprescribing of Sedative-Hypnotics in Primary Care
Burry, Lisa , Turner, Justin P. , Tannenbaum, Cara , Cho, Hyung J. , Gathecha, Evelyn , Kisuule, Flora, Vijenthira, Abi , Turner, Justin , Morgenthaler, Timothy, Morgenthaler, Timothy I. , Soong, Christine

Mayo Clinic

Annals of Pharmacotherapy | July 24, 2021 | Volume: 56 | Issue: 4 | Pages: 463-474

10.1177/10600280211033022 | PMID 34301151 Get It

Objective: To describe interventions that target patient, provider, and system barriers to sedative-hypnotic (SH) deprescribing in the community and suggest strategies for healthcare teams. Data Sources: Ovid MEDLINE ALL and EMBASE Classic + EMBASE (March 10, 2021). Study Selection and Data Extraction: English-language studies in primary care settings. Data Synthesis: 20 studies were themed as patient-related and prescriber inertia, physician skills and awareness, and health system constraints. Patient education strategies reduced SH dose for 10% to 62% of participants, leading to discontinuation in 13% to 80% of participants. Policy interventions reduced targeted medication use by 10% to 50%. Relevance to Patient Care and Clinical Practice: Patient engagement and empowerment successfully convince patients to deprescribe chronic SHs. Quality improvement strategies should also consider interventions directed at prescribers, including education and training, drug utilization reviews, or computer alerts indicating a potentially inappropriate prescription by medication, age, dose, or disease. Educational interventions were effective when they facilitated patient engagement and provided information on the harms and limited evidence supporting chronic use as well as the effectiveness of alternatives. Decision support tools were less effective than prescriber education with patient engagement, although they can be readily incorporated in the workflow through prescribing software. Conclusions: Several strategies with demonstrated efficacy in reducing SH use in community practice were identified. Education regarding SH risks, how to taper, and potential alternatives are essential details to provide to clinicians, patients, and families. The strategies presented can guide community healthcare teams toward reducing the community burden of SH use.
Double Frost Suture Technique for Simultaneous Skin Grafting of the Upper and Lower Eyelids
DeMaria, Lauren N., Tran, Ann Q. , Tooley, Andrea A. , North, Victoria S. , Flores, Roberto L. , Lisman, Richard D. , Belinsky, Irina

Mayo Clinic

Ophthalmic Plastic & Reconstructive Surgery | July 23, 2021 | Volume: 37 | Issue: 6 | Pages: e217-e221

10.1097/iop.0000000000002032 | PMID 34297708 Get It

The double Frost suture is a useful supplement to the reconstruction of ipsilateral upper and lower eyelid defects with full-thickness skin grafts. This technique involves silk traction sutures that overlap the upper and lower eyelids to place them on maximal stretch after placement of 2 full-thickness skin grafts. It has the added benefit of protecting the cornea and compressing both grafts under 1 bolster. The authors illustrate this technique in 2 pediatric cases—a congenital melanocytic kissing eyelid nevus and a periocular burn. Each case resulted in large upper and lower anterior lamellar defects, which were reconstructed with supraclavicular and retroauricular free skin grafts. The double Frost sutures counter vertical cicatricial forces during graft healing, obviating the need for staged procedures. Both described cases resulted in excellent graft survival with minimal contracture.
Laparoscopic transversus abdominis plane block versus intrathecal analgesia in robotic colorectal surgery
Calini, Giacomo , Aziz, Mohamed A. Abd El , Solafah, A, Saeed, Hasan Abdulhadi Isa Ali, Lovely, Jenna K. , D’Angelo, A-L, Calini, G , Abd El Aziz, Mohamed A , Solafah, A , Lovely, J K , Larson, David W. , Kelley, Scott R. , Colibaseanu, Dorin , Behm, Kevin T.

Mayo Clinic

British Journal of Surgery | July 23, 2021 | Volume: 108 | Issue: 11 | Pages: e369-e370

10.1093/bjs/znab294 | PMID 34459868 Get It

Invited Commentary: Contextualization of LI-RADS Reporting
Yano, Motoyo

Mayo Clinic

RadioGraphics | July 23, 2021 | Volume: 41 | Issue: 5 | Pages: E151-E152

10.1148/rg.2021210057 | PMID 34297632 Get It

E-cigarette or vaping product use-associated lung injury (EVALI) masquerading as COVID-19
Ganne, Nandita, Palraj, Raj , Husted, Elizabeth, Shah, Ishan , Palraj, Raj , Shah, Ishan

Mayo Clinic

BMJ Case Reports | July 23, 2021 | Volume: 14 | Issue: 7 | Pages: e243885

10.1136/bcr-2021-243885 | PMID 34301688 Get It

SARS-CoV-2, the novel coronavirus causing COVID-19, has caused a global pandemic resulting in over 4 million deaths globally (data current as of 14 July 2021). E-cigarette or vaping product use-associated lung injury (EVALI) is a type of acute lung injury of unclear pathogenesis. The two pathologies present with overlapping clinical symptoms, laboratory values and imaging, making them difficult to distinguish, especially in the setting of a global COVID-19 pandemic. We present the case of a 32-year-old woman treated for COVID-19 despite multiple negative SARS CoV-2 PCR tests and nucleocapsid antibody test. On further investigation, she endorsed use of E-cigarettes and was subsequently diagnosed with EVALI. The patient was treated with oral and intravenous steroids, resulting in significant improvement in her symptoms. This case highlights the challenge of diagnosing rarer aetiologies of respiratory distress during the COVID-19 pandemic.
Imaging of the Vagina: Spectrum of Disease with Emphasis on MRI Appearance
Zulfiqar, Maria , Shetty, Anup S. , Yano, Motoyo , McGettigan, Melissa , Itani, Malak , Naeem, Muhammad , Ratts, Valerie , Siegel, Cary , Naeem, Muhammad , Shetty, Anup , Ratts, Valerie S, Siegel, Cary Lynn , Zulfiqar, Maria , Itani, Malak , Naeem, Muhammad

Mayo Clinic

RadioGraphics | July 23, 2021 | Volume: 41 | Issue: 5 | Pages: 1549-1568

10.1148/rg.2021210018 | PMID 34297630 Get It

Variation in opioid prescribing patterns after abdominal transplant surgery
Sussman, Jon , Calderon, Esteban , Ubl, Daniel S. , Croome, Kristopher P. , Moss, Adyr A. , Habermann, Elizabeth B. , Mathur, Amit K. , Taner, C. Burcin , Mathur, Amit , Croome, Kris P , Habermann, Elizabeth , Calderon, Esteban , Heimbach, Julie K.

Mayo Clinic

Clinical Transplantation | July 23, 2021 | Volume: 35 | Issue: 10 | Pages: No page available

10.1111/ctr.14439 | PMID 34297440 Get It

AbstractBackgroundOpioids are associated with negative transplant outcomes. We sought to identify patient and center effects on over‐prescribing of opioids (> 200 OME (oral morphine equivalents)).Study designClinical and opioid prescription data (2014–2017) were collected from three academic transplant centers for kidney (KT), liver (LT), and simultaneous liver‐kidney transplant (SLK) patients. Multivariable models were used to identify predictors of opioid over‐prescribing at discharge and the occurrence of refill prescriptions at 90 days.ResultsThree‐thousand seven‐hundred and two patients underwent transplant in the cohort (KT: n = 2358, LT: n = 1221, SLK: n = 123). More than 80% of recipients were over‐prescribed opioids at discharge (Median OME (mOME) = 300 (IQR 225–375). LT and SLK had the largest prescription size (LT mOME 338 (IQR 300–450); SLK mOME 338 (IQR 225–450) and refill rate (LT: 64%, SLK 59%) (all, P < .001). Multivariable analysis indicated that transplant center was a significant predictor of opioid over‐prescription after KT and LT (all, P < .001); older age (in KT) and length of stay (LOS) (in LT) were protective factors (both, P < .05). Refill occurrence was associated with initial prescription size and was reduced by older age and initial LOS (all, P < .05).ConclusionsThe wide variation in opioid prescribing patterns has implications for transplant practice innovation, guideline development, and further study.
Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B‐cell lymphoma
Oluwole, Olalekan O. , Bouabdallah, Krimo , Guibert, Sophie de , Bartlett, Nancy L. , Lin, Yi , Deol, Abhinav , McSweeney, Peter A., Kersten, Marie José , Jacobson, Caron A. , Farooq, Umar , Thiéblemont, Catherine , Timmerman, John M. , Stiff, Patrick J. , Avivi, Irit , Tzachanis, Dimitrios , McLeroy, Jeff, Rossi, John M. , Johnson, Lisa D. , Goyal, Lovely, Farooq, Umar , Bartlett, Nancy L , Johnson, Lisa D S , Oluwole, Olalekan O , Lin, Yi , Muñoz, Javier , Vose, Julie M. , Goy, Andre Henri , Minnema, Monique C , Kim, Jaeyeon , Bashir, Zahid , Zheng, Yan , Meerten, Tom van

Mayo Clinic

British Journal of Haematology | July 23, 2021 | Volume: 194 | Issue: 4 | Pages: 690-700

10.1111/bjh.17527 | PMID 34296427 Get It

SummaryZUMA‐1 (NCT02348216) examined the safety and efficacy of axicabtagene ciloleucel (axi‐cel), an autologous CD19‐directed chimaeric antigen receptor (CAR)‐T cell therapy, in refractory large B‐cell lymphoma. To reduce treatment‐related toxicity, several exploratory safety management cohorts were added to ZUMA‐1. Specifically, cohort 6 investigated management of cytokine release syndrome (CRS) and neurologic events (NEs) with prophylactic corticosteroids and earlier corticosteroid and tocilizumab intervention. CRS and NE incidence and severity were primary end‐points. Following leukapheresis, patients could receive optional bridging therapy per investigator discretion. All patients received conditioning chemotherapy (days −5 through −3), 2 × 106 CAR‐T cells/kg (day 0) and once‐daily oral dexamethasone [10 mg, day 0 (before axi‐cel) through day 2]. Forty patients received axi‐cel. CRS occurred in 80% of patients (all grade ≤2). Any grade and grade 3 or higher NEs occurred in 58% and 13% of patients respectively. Sixty‐eight per cent of patients did not experience CRS or NEs within 72 h of axi‐cel. With a median follow‐up of 8·9 months, objective and complete response rates were 95% and 80% respectively. Overall, prophylactic corticosteroids and earlier corticosteroid and/or tocilizumab intervention resulted in no grade 3 or higher CRS, a low rate of grade 3 or higher NEs and high response rates in this study population.
Expectations of and for Clerkship Directors 2.0: A Collaborative Statement from the Alliance for Clinical Education
Morgenstern, Bruce Z. , Roman, Brenda , DeWaay, Deborah , Malloy, Erin , Reddy, Rishindra M. , Rutter, Annie , Soni, Madhu , Starr, Stephanie R. , Sutton, Jill M. , Wald, David A., Pangaro, Louis N. , Roman, Brenda J B , Malloy, Erin , Rutter, Ann E , Starr, Stephanie, Golden, William Christopher , Salas, Rachel Marie E.

Mayo Clinic

Teaching and Learning in Medicine | July 23, 2021 | Volume: 33 | Issue: 4 | Pages: 343-354

10.1080/10401334.2021.1929997 | PMID 34294018 Get It